John is a 62-year-old male admitted to the ICU with septic shock secondary to pneumonia. He has a history of hypertension and type 2 diabetes mellitus. He has been receiving stress dose hydrocortisone 50 mg IV every 6 hours for 3 days. The ICU team is considering discontinuing hydrocortisone and asks for your recommendation on tapering versus abrupt cessation. His current vasopressor support is low-dose norepinephrine.

Based on recent evidence, what should the pharmacist counsel the ICU team regarding hydrocortisone discontinuation in this patient?

Maria is a 55-year-old female with septic shock who has been receiving stress dose hydrocortisone for 4 days. The ICU team has initiated a taper by reducing dosing frequency from every 6 hours to every 12 hours. She remains on low-dose vasopressors. As the clinical pharmacist, you are asked about monitoring priorities during hydrocortisone tapering.

What is the most important clinical parameter to monitor closely during the hydrocortisone taper in this patient?

David is a 70-year-old male with septic shock treated with stress dose hydrocortisone for 5 days. The ICU team is debating whether to taper or abruptly stop hydrocortisone. They want to understand the impact of tapering on ICU length of stay and mechanical ventilation duration to inform their decision.

According to recent evidence, what are the expected effects of hydrocortisone tapering on ICU length of stay and mechanical ventilation duration?